Which autoimmune encephalitis is not responsive to intravenous immunoglobulin (IVIG)?

Classical Paraneoplastic Encephalitis Shows Poor Response to IVIG

Classical paraneoplastic encephalitis, particularly those with antibodies against intracellular antigens (such as anti-Hu, anti-Yo, anti-Ma2), demonstrates notably poor responsiveness to IVIG compared to other autoimmune encephalitis subtypes. This is because these conditions are primarily T-cell mediated rather than antibody-mediated, making B-cell targeted therapies like IVIG less effective 1.

Understanding the Mechanism

The key distinction lies in the pathophysiology:

• Antibody-mediated AE (surface antigens like NMDAR, LGI1): IVIG can be effective as it targets circulating antibodies
• Cell-mediated AE (intracellular antigens): IVIG has limited efficacy because the immune response is driven by cytotoxic T-cells, not by pathogenic antibodies accessible to immunoglobulin therapy

Treatment Response by Antibody Type

According to the 2021 guideline consensus 1:

• Only 48.5% of clinicians selected corticosteroids combined with IVIG or plasmapheresis as first-line therapy for classical paraneoplastic encephalitis, compared to 63% for NMDAR encephalitis
• Cyclophosphamide is preferred over rituximab (which works similarly to IVIG by targeting B-cells) for known or highly suspected cell-mediated autoimmunity 1

Anti-GAD65 Encephalitis: Another Poor Responder

Anti-GAD65 autoimmune encephalitis also demonstrates poor IVIG responsiveness 2:

• Overall IVIG effectiveness: only 36.71%
• In epilepsy patients: 32.69% response rate
• In cerebellar ataxia: 55.56% response rate
• In tumor-associated cases: 42.11% response rate

Except for stiff-person syndrome (77.78% response), anti-GAD65 encephalitis generally shows poor response to IVIG 2.

Clinical Algorithm for Treatment Selection

When antibody results are pending 1:

1. Assess clinical clues:

   • Faciobrachial dystonic seizures or typical NMDAR presentation → likely antibody-mediated → IVIG appropriate
   • Known cancer or high cancer risk → likely cell-mediated → avoid IVIG monotherapy

2. For classical paraneoplastic syndrome:

   • Start with high-dose corticosteroids
   • If no response after 2-4 weeks, escalate to cyclophosphamide (not rituximab or additional IVIG)
   • IVIG should not be relied upon as primary therapy

3. For antibody-mediated AE:

   • IVIG is appropriate as first-line (alone or with steroids)
   • Consider rituximab for second-line

Important Caveats

• Tumor removal is paramount in paraneoplastic cases and often more effective than any immunotherapy 1
• The poor response to IVIG in paraneoplastic encephalitis reflects irreversible neuronal damage from cytotoxic T-cell attack, not treatment failure per se
• Do not delay second-line agents (cyclophosphamide) in paraneoplastic cases hoping IVIG will work—it typically won't 1